NEW YORK (GenomeWeb News) – BioSeek said today that it has expanded an agreement with the Environmental Protection Agency, under which EPA will use the firm's BioMap in the second phase of its ToxCast program.

Under the agreement, EPA will use the BioMap, which employs cell-based disease models to generate activity profiles of potential drugs, to study the biological effects of certain chemicals and help the agency select new candidates. BioSeek also will use its technology to assess the impact of these chemicals on the environment and on human health.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.